Lilly diabetes med linked to pancreatitis

A fast-growing Eli Lilly med may be held back by a new warning linking it to acute pancreatitis. After 30 reports of pancreatitis in patients using the injectable diabetes drug Byetta--five of which led to serious complications such as kidney failure--the FDA has asked Lilly and its partner on the drug, Amylin, to revise its labeling.

With $430.2 million in 2006 sales, Byetta delivered some $219 million in revenues to Lilly. The rest went to Amylin, accounting for 90 percent of that company's sales. Amylin stock fell sharply on the news.

- check out the report from the Indianapolis Star

Related Articles:
In speech, Lilly CEO calls for drug monitoring. Report
Lilly developing biotech drugs the old-fashioned way. Report
Amylin shares shoot up on Phase II Byetta results. Report
Diabetes epidemic triggers soaring drug market. Report

Read more on: Eli Lilly | Diabetes | Amylin

Suggested Articles

Merck KGaA has big plans for a site in Switzerland where it intends to knit together biologics development and manufacturing. 

Biocon’s key biosimilars plant in Bengaluru, India, has gotten mixed reviews from the FDA and has now received a Form 483 with five observations.

Eli Lilly and Incyte are investing heavily in JAK inhibitor Olumiant's chances in atopic dermatitis, but does it stand a chance against Dupixent?